Novartis and Gilead’s CAR-T therapies have been approved in Europe – and the UK’s NICE immediately slapped down the latter, saying it is too expensive for regular NHS use in England and Wal
England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL)
NICE has continued to reject Roche’s Perjeta (pertuzumab) in its use to prevent early-stage HER2-positive breast cancer from recurring after surgery, after reconsidering evidence in the lig
